In clinical trials of sitagliptin as monotherapy and sitagliptin as part of combination therapy with metformin, rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
En ensayos clínicos de sitagliptina como monoterapia y sitagliptina como parte de la terapia combinada con metformina, las tasas de hipoglucemia comunicadas con sitagliptina fueron similares a las tasas en los pacientes que tomaban placebo.